Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Sionna Therapeutics, Inc.NASDAQ: SION
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow growth accelerates
Q1 FY2026 free cash flow of $21.84M (cash outflow) rose 33.4% year over year, ahead of the +28.8% change in trailing-twelve-month free cash flow. Sequentially, it rose 29.8% from the prior quarter. Over 3 fiscal years it compounded at +20.7% a year.
Context
- Free cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +33.4% holds above the trailing-twelve-month pace of +28.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (66.67M) USD
- Year-over-year change
- -26.2%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (66.67M) | -26.2% |
| FY2024 | 2024-12-31 | (52.81M) | -17.8% |
| FY2023 | 2023-12-31 | (44.82M) | -18.1% |
| FY2022 | 2022-12-31 | (37.94M) | — |
Free Cash Flow vs competitors
How SION compares with its peers on the latest reported figures
- SION's LTM Mar 2026 free cash flow of $72.14M is the 9th largest of the 11 companies compared; the peer median is $117.23M.
- Its year-over-year change of +28.8% is the 6th highest of 11, against a peer median of +33.5%.
- Over three fiscal years its annual growth of +20.7% compares with a peer median of +21.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $511.87M | -20.8% | +21.7% | — | |
| LTM Jun 2026 | $339.06M | +81.8% | +52.9% | — | |
| LTM Sep 2026 | $259.45M | +42.8% | +26.5% | 231652.7% | |
| LTM Sep 2026 | $238.7M | +24.3% | +90.7% | — | |
| LTM Mar 2026 | $122.13M | -277.7% | +3.7% | 610.6% | |
| LTM Sep 2026 | $112.33M | +69.7% | — | 42.2% | |
| LTM Sep 2026 | $92.64M | -39.5% | — | 136.5% | |
| LTM Mar 2026 | $78.49M | +68.7% | +19.0% | 363.2% | |
| LTM Mar 2026 | $72.14M | +28.8% | +20.7% | — | |
| LTM Mar 2026 | $47.23M | +272.2% | — | 15.0% | |
| LTM Mar 2026 | $37.5M | -23.0% | -14.4% | 8.8% | |
| Peer median (excluding SION) | $117.23M | +33.5% | +21.7% | 136.5% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.